BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37578312)

  • 21. Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.
    Behera A; Banerjee I; De K; Munda RN; Chattopadhayay S; Samanta A; Sarkar B; Ganguly S; Misra M
    Amino Acids; 2013 Mar; 44(3):933-46. PubMed ID: 23090293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study.
    Anzola-Fuentes LK; Chianelli M; Galli F; Glaudemans AW; Martin Martin L; Todino V; Migliore A; Signore A
    EJNMMI Res; 2016 Dec; 6(1):49. PubMed ID: 27259576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
    Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
    Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
    Sun H; Jiang XF; Wang S; Chen HY; Sun J; Li PY; Ning G; Zhao YJ
    Endocrine; 2007 Jun; 31(3):305-10. PubMed ID: 17906380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
    J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma].
    Czepczyński R; Kosowicz J; Ziemnicka K; Mikołajczak R; Gryczyńska M; Sowiński J
    Endokrynol Pol; 2006; 57(4):431-5. PubMed ID: 17006849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice.
    Li Y; Si JM; Zhang J; Du J; Wang F; Jia B
    World J Gastroenterol; 2005 Jul; 11(25):3953-7. PubMed ID: 15991301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
    J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.
    Guggenberg EV; Mikolajczak R; Janota B; Riccabona G; Decristoforo C
    J Pharm Sci; 2004 Oct; 93(10):2497-506. PubMed ID: 15349959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
    Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
    Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma.
    Guo H; Miao Y
    J Nucl Med; 2014 Dec; 55(12):2057-63. PubMed ID: 25453052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.
    Gabriel M; Froehlich F; Decristoforo C; Ensinger C; Donnemiller E; von Guggenberg E; Heute D; Moncayo R
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):330-41. PubMed ID: 14625664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland.
    Kainz H; Bale R; Donnemiller E; Gabriel M; Kovacs P; Decristoforo C; Moncayo R
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1155-9. PubMed ID: 12811420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
    von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
    Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy.
    Nocuń A; Chrapko B; Gołębiewska R; Stefaniak B; Czekajska-Chehab E
    Nucl Med Commun; 2011 Jun; 32(6):522-9. PubMed ID: 21383640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in graves' disease.
    Gabriel M; Decristoforo C; Moncayo R
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1267. PubMed ID: 12418470
    [No Abstract]   [Full Text] [Related]  

  • 39. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
    Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
    Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.